Maria Glymenaki1, Gurdeep Singh, Andrew Brass, Geoffrey Warhurst, Andrew J McBain, Kathryn J Else, Sheena M Cruickshank. 1. *Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom; †Bio-Health Informatics Group, School of Computer Science, University of Manchester, Manchester, United Kingdom; and ‡Infection, Injury and Inflammation Research Group, Division of Medicine and Neurosciences, University of Manchester and Salford Royal Hospitals NHS Trust, Salford, United Kingdom.
Abstract
BACKGROUND: Inflammatory bowel disease (IBD) is associated with an inappropriate immune response to the gut microbiota. Notably, patients with IBD reportedly have alterations in fecal microbiota. However, the colonic microbiota occupies both the gut lumen and the mucus covering the epithelium. Thus, information about mucus-resident microbiota fails to be conveyed in the routine microbiota analyses of stool samples. Further, studies analyzing microbiota in IBD have mainly focused on stool samples taken after onset of inflammation. Our objective was to investigate both temporal and spatial changes in colonic microbiota communities preceding the onset of colitis. METHODS: We studied mucus and stool microbiota using a spontaneous model of colitis, the mdr1a mouse, and their respective wild-type littermate controls in a time series mode. RESULTS: Using this approach we have shown that microbial dysbiosis was evident in the mucus but not stools, with reduced abundance of Clostridiales evident in the mucus but not stools, of colitis-prone mice mdr1a mice 12 weeks before the onset of detectable inflammation. This altered microbial composition was coupled with a significantly thinner mucus layer. On emergence of inflammation, dysbiosis was evident in the stools and at this time point, the spatial segregation between microbiota and host tissue was also disrupted, correlating with worsened inflammation. Our results reveal that microbial dysbiosis is detectable before changes in the stools. Importantly, dysbiosis in the mucus layer preceded development of colitis. CONCLUSIONS: Our data reveal the importance of mucus sampling for understanding the underlying etiology of IBD and fundamental processes underlying disease progression.
BACKGROUND:Inflammatory bowel disease (IBD) is associated with an inappropriate immune response to the gut microbiota. Notably, patients with IBD reportedly have alterations in fecal microbiota. However, the colonic microbiota occupies both the gut lumen and the mucus covering the epithelium. Thus, information about mucus-resident microbiota fails to be conveyed in the routine microbiota analyses of stool samples. Further, studies analyzing microbiota in IBD have mainly focused on stool samples taken after onset of inflammation. Our objective was to investigate both temporal and spatial changes in colonic microbiota communities preceding the onset of colitis. METHODS: We studied mucus and stool microbiota using a spontaneous model of colitis, the mdr1amouse, and their respective wild-type littermate controls in a time series mode. RESULTS: Using this approach we have shown that microbial dysbiosis was evident in the mucus but not stools, with reduced abundance of Clostridiales evident in the mucus but not stools, of colitis-prone micemdr1amice 12 weeks before the onset of detectable inflammation. This altered microbial composition was coupled with a significantly thinner mucus layer. On emergence of inflammation, dysbiosis was evident in the stools and at this time point, the spatial segregation between microbiota and host tissue was also disrupted, correlating with worsened inflammation. Our results reveal that microbial dysbiosis is detectable before changes in the stools. Importantly, dysbiosis in the mucus layer preceded development of colitis. CONCLUSIONS: Our data reveal the importance of mucus sampling for understanding the underlying etiology of IBD and fundamental processes underlying disease progression.
Authors: Deepak Selvakumar; Dolan Evans; Katharine Z Coyte; John McLaughlin; Andy Brass; Laura Hancock; Sheena Cruickshank Journal: Frontline Gastroenterol Date: 2022-06-15
Authors: Martha J Shrubsole; Anthony A Fodor; Shan Sun; Xiangzhu Zhu; Xiang Huang; Harvey J Murff; Reid M Ness; Douglas L Seidner; Alicia A Sorgen; Ivory C Blakley; Chang Yu; Qi Dai; M Andrea Azcarate-Peril Journal: Sci Rep Date: 2021-07-21 Impact factor: 4.379
Authors: M Glymenaki; A Barnes; S O'Hagan; G Warhurst; A J McBain; I D Wilson; D B Kell; K J Else; S M Cruickshank Journal: Sci Rep Date: 2017-08-18 Impact factor: 4.379